Skip Navigation Links.
Collapse <span class="m110 colortj mt20 fontw700">Volume 12 (2024)</span>Volume 12 (2024)
Collapse <span class="m110 colortj mt20 fontw700">Volume 11 (2023)</span>Volume 11 (2023)
Collapse <span class="m110 colortj mt20 fontw700">Volume 10 (2022)</span>Volume 10 (2022)
Collapse <span class="m110 colortj mt20 fontw700">Volume 9 (2021)</span>Volume 9 (2021)
Collapse <span class="m110 colortj mt20 fontw700">Volume 8 (2020)</span>Volume 8 (2020)
Collapse <span class="m110 colortj mt20 fontw700">Volume 7 (2019)</span>Volume 7 (2019)
Collapse <span class="m110 colortj mt20 fontw700">Volume 6 (2018)</span>Volume 6 (2018)
Collapse <span class="m110 colortj mt20 fontw700">Volume 5 (2017)</span>Volume 5 (2017)
Collapse <span class="m110 colortj mt20 fontw700">Volume 4 (2016)</span>Volume 4 (2016)
Collapse <span class="m110 colortj mt20 fontw700">Volume 3 (2015)</span>Volume 3 (2015)
Collapse <span class="m110 colortj mt20 fontw700">Volume 2 (2014)</span>Volume 2 (2014)
Collapse <span class="m110 colortj mt20 fontw700">Volume 1 (2013)</span>Volume 1 (2013)
American Journal of Medical Case Reports. 2015, 3(6), 163-166
DOI: 10.12691/AJMCR-3-6-4
Case Report

Parietal Plasmacytoma: An Ominous Sign of Disease Recurrence

Narjust Duma MD1, , Dhruvesh Patel2 and Thayer Nasereddin2

1Rutgers-New Jersey Medical School, Newark, New Jersey, 07103, United States

2Saint George’s University, True blue, 38901, Grenada

Pub. Date: May 15, 2015

Cite this paper

Narjust Duma MD, Dhruvesh Patel and Thayer Nasereddin. Parietal Plasmacytoma: An Ominous Sign of Disease Recurrence. American Journal of Medical Case Reports. 2015; 3(6):163-166. doi: 10.12691/AJMCR-3-6-4

Abstract

Plasmacytomas located in the central nervous system are rareentities; with no pathognomonic clinical or radiologic features histology is required for a definite diagnosis. We present a case of a dural plasmacytoma as the manifestation of disease recurrence in a patient with systemic multiple myeloma. 51 year old male with history of IgG kappa myeloma, who underwent complete remission after an autologous bone marrow transplant presented to the clinic 10 months post-remission complaining of a “head mass”. On physical examination, he was found to have a large soft mass in the parietal area. On MRI the lesion was described as an extra-axial mass, 5.5 cm x5cm diameter, with diffuse enhancement of the dura. Biopsy of the mass revealed anextramedullary plasmacytoma. At that time, his M spike and immunoglobulins levels were unremarkable. Several months after the presentation of the parietal mass, the patient developed recurrence of disease. He underwent a second autologous bone marrow transplant that markedly improved the size of the plasmacytoma. Patient achieved a complete remission after the second transplant. However, 6 months later the dural plasmacytoma increased in size and once again and his myeloma markers remained within normal levels. Unfortunately, recurrence of the multiple myeloma occurred several months later and despite several cycles of chemotherapy, the patient continued to have progression of disease. He then decided for a more conservative treatment and was sent to home hospice. Central nervous system plasmacytomas can present as solitary lesions or as part of systemic multiple myeloma, these tumors tend to have a direct relationship with the activity of the disease and can present as an early sign of recurrence despite normal multiple myeloma markers on peripheral blood.

Keywords

dural plasmacytoma, multiple myeloma, solitary plasmacytoma, multiple myeloma recurrence

Copyright

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]  “Criteria for the Classification of Monoclonal Gammopathies, Multiple Myeloma and Related Disorders: A Report of the International Myeloma Working Group.” British Journal of Haematology 121.5, 2003: 749-57.
 
[2]  Ferrari, S., C. Tecchio, G. Turri, S. Richelli, C. Ghimenton, S. Monaco, and G. Todeschini. “Unusual Case of Solitary Intraparenchymal Brain Plasmacytoma.” Journal of Clinical Oncology 2012; 30.33: E350-352.
 
[3]  Senapati SB, Mishra SS, Dhir MK, Das S, Tripathy K. A case of multiple myeloma presenting as scalp swelling with intracranial extension. Journal of Neurosciences in Rural Practice. 2013; 4(4): 445-448.
 
[4]  Daghighi MH, Poureisa M, Shimia M, Mazaheri-Khamene R, Daghighi S. Extramedullary Plasmacytoma Presenting as a Solitary Mass in the Intracranial Posterior Fossa. Iranian Journal of Radiology. 2012; 9(4): 223-226.
 
[5]  Eum JH, Jeibmann A, Wiesmann W, Paulus W, Ebel H. Multiple myeloma manifesting as an intraventricular brain tumor. J Neurosurg. 2009; 110: 737-739.
 
[6]  Cerase A, Tarantino A, Gozzetti A, Muccio CF, Gennari P, Monti L, Di Blasi A, Venturi C. Intracranial involvement in plasmacytomas and multiple myeloma: a pictorial essay. Neuroradiology. 2008; 50:665-674.
 
[7]  Wavre A, Baur AS, Betz M, Muhlematter D, Jotterand M, Zaman K, Ketterer N. Case study of intracerebral plasmacytoma as an intial presentation of multiple myeloma. Neuro Oncol.2007; 9: 370-372.
 
[8]  Higurashi M, Yagishita S, Fujitsu K, Kitsuta Y, Takemoto Y, Osano S. Plasma cell myeloma of the skull base: report of two cases. Brain Tumor Pathol. 2004; 21:135-141.
 
[9]  Mantyla R, Kinnunen J, Bohling T. Intracranial plasmacytoma: a case report. Neuroradiology 1996; 38:646-649.
 
[10]  Coppeto JR, Monteiro ML, Collias J, Uphoff D, Bear L. Foster-Kennedy syndrome caused by solitary intracranial plasmacytoma. Surg Neurol. 1983; 19:267-272.
 
[11]  Trimble GX. Plasmacytoma primary in the brain. New Eng J Med. 1973; 15:582.
 
[12]  Webb HE, Harrison EG, Masson JK, ReMineWH: Solitary extramedullary myeloma (plasmacytoma) of the upper part of the respiratory tract and oropharynx. Cancer 1962 15:1142-1155.
 
[13]  Wisniewski T, Sisti M, Inhirami G, Knowles DM, Powers JM: Intracerebral solitary plasmacytoma. Neurosurgery 1990 27: 826-829.
 
[14]  Kyle, R. A., and S. V. Rajkumar. “Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma.” Leukemia 23.1 (2009): 3-9.
 
[15]  Durie, B. G. M., et al. “International uniform response criteria for multiple myeloma.” Leukemia 20.9 (2006): 1467-1473.
 
[16]  Greipp, Philip R., et al. “International staging system for multiple myeloma.” Journal of Clinical Oncology 23.15 (2005): 3412-3420.
 
[17]  Attanasio G, Viccaro M, Barbaro M, De Seta E, Filipo R. Extramedullary plasmacytoma of paranasal sinuses. A combined therapeutic strategy. ActaOtorhinolaryngologicaItalica. 2006; 26(2):118-120.
 
[18]  Galieni P, Cavo M, Pulsoni A, et al: Clinical outcome of extramedullary plasmacytoma. Haematologica 2000, 85:47-51.
 
[19]  Bahadori M, Liebow AA: Plasma cell granulomas of the lung. Cancer, 1973, 31:191-208.
 
[20]  Cerase A, Tarantino A, Gozzetti A, Muccio CF, Gennari P, Monti L, et al. Intracranial involvement in plasmacytomas and multiple myeloma: a pictorial essay. Neuroradiology. 2008; 50(8):665-74.
 
[21]  Rahmah N, Brotoarianto H, Andor E, Kusnarto G, Muttaqin Z, Hongo K. Dural plasmacytoma mimicking meningioma in a young patient with multiple myeloma. Biomed Imaging Interv J. 2009; 5(2).
 
[22]  Provenzale JM, Schaefer P, Traweek ST, Ferry J, Moore JO, Friedman AH, et al. Craniocerebral plasmacytoma: MR features. AJNR Am J Neuroradiol. 1997; 18(2):389-92.
 
[23]  Engelsma RJ, De Bree R, Janssen JJ, Scheeren RA. Plasmacytoma of the mastoid bone: Solitary and systemic. J Laryngol Otol. 2000; 114:378-80.
 
[24]  LorsbachRB, Hsi ED, Dogan A, Fend F. Plasma cell myeloma and related neoplasms. Am J ClinPathol. 2011; 136:168-82.
 
[25]  Kyle RA, Therneau TM, RajkumarSV, Larson DR, Plevak MF, Melton LJ., 3 rd Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades. Cancer. 2004; 101:2667-74.
 
[26]  Gozzetti A, Cerase A, Lotti F, Rossi D, Palumbo A, Petrucci MT, et al. Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: A retrospective survey of 50 patients. Cancer. 2012; 118:1574-84.